AirNet Technology raises $180 million in digital assets offering
JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), currently trading at $0.88 with a market capitalization of ~$61 million, has received a written notice from Nasdaq indicating that the company’s share price has fallen below the minimum $1.00 per share requirement for continued listing, the biopharmaceutical company announced Friday.
The notice, dated July 11, stated that InflaRx’s common shares had closed below the threshold for the last 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
The company has been granted an initial 180-day period until January 7, 2026, to regain compliance with the minimum bid price rule. If unsuccessful, InflaRx may apply to transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market, potentially providing an additional 180 days until July 6, 2026, to meet requirements.
According to the company’s statement, the notice has no immediate effect on the listing or trading of InflaRx’s common shares. The firm plans to monitor its share price and consider available options to regain compliance.
InflaRx, founded in 2007, focuses on developing anti-inflammatory therapeutics by targeting the complement system. The company has operations in Jena and Munich, Germany, as well as Ann Arbor, Michigan.
This information is based on a press release issued by the company.
In other recent news, InflaRx NV has faced significant developments concerning its drug pipeline and financial outlook. The company reported a decision to halt the Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) following an Independent Data Monitoring Committee recommendation due to insufficient treatment effects. This led Raymond James to downgrade InflaRx’s stock from Strong Buy to Outperform and reduce the price target from $13.00 to $2.00, while Guggenheim maintained its Buy rating with a $10.00 target. Despite the setback, InflaRx is redirecting its focus toward INF904, with a Phase 2a study in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) expected soon. Analysts, including those from Cantor Fitzgerald, see potential in INF904, suggesting it could outperform current market alternatives. InflaRx’s financial stability appears robust, with cash reserves projected to support operations into 2027. The company’s recent first-quarter earnings report showed an EPS of (€0.13), better than the anticipated (€0.21). InflaRx’s strategic shifts and financial resilience continue to attract attention from investors and analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.